Evidence map›Paper›PMID 41398940›Full record

ArticleBMC cancer2025

The prognostic value of systemic inflammatory response index (SIRI) and CD8 + tumor-infiltrating lymphocytes for patients with localized undifferentiated pleomorphic sarcoma of soft tissue.

Hiroshi Kobayashi, Hiroyuki Abe, Tetsuo Ushiku, Yutaka Nezu, Toru Hiruma, Shintaro Iwata, Akira Kawai, Tomoaki Mori, Robert Nakayama, Naohiro Makise and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hiroshi KobayashiDepartment of Orthopaedic Surgery, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. hkobayashi-tky@umin.ac.jp.
Hiroyuki AbeDepartment of Pathology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113- 8655, Japan.
Tetsuo UshikuDepartment of Pathology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113- 8655, Japan.
Yutaka NezuDepartment of Musculoskeletal Tumor Surgery, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.
Toru HirumaDepartment of Musculoskeletal Tumor Surgery, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.
Shintaro IwataDivision of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Akira KawaiDivision of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Tomoaki MoriDepartment of Orthopedic Surgery, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Robert NakayamaDepartment of Orthopedic Surgery, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Naohiro MakiseDivision of Pathology, Chiba Cancer Center, Chiba, 260-0801, Japan.
Tsukasa YonemotoDivision of Orthopedic Surgery, Chiba Cancer Center, Chiba, 260-0801, Japan.
Sakae TanakaDepartment of Orthopaedic Surgery, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory blood markers and tumor-infiltrating lymphocytes (TILs) are associated with the prognosis of various cancers. However, reports on their value as prognostic markers in soft tissue undifferentiated pleomorphic sarcoma (UPS) are limited. We aimed to clarify the predictive value of these markers for the prognosis of patients with UPS, focusing on resectable tumors of the extremities and trunk.

methodsThis retrospective analysis included data from 103 patients with localized UPS in the extremities and trunk. The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), and systemic inflammatory response index (SIRI) were calculated, and the median values were determined as cut-off values. Immunohistochemical staining of CD8 + TILs was also performed. Disease-specific overall survival (DOS) and distant metastasis-free survival (DMFS) rates were analyzed using the Kaplan-Meier method, and prognostic factors were identified using the Cox proportional hazards model.

resultsAmong the inflammatory blood markers, SIRI was found to be a sensitive prognostic factor, and a high SIRI was associated with worse DOS (P = 0.16) and DMFS (P = 0.09). Although CD8 + TILs were not associated with DOS (P = 0.67), high CD8 + TILs correlated with improved DMFS (P = 0.20). Only tumor size > 10 cm was significantly associated with worse DMFS (P = 0.02) in the univariate analysis, while inflammatory blood markers and CD8 + TIL showed no correlation. The combination of SIRI and CD8 + TILs revealed that high CD8 + TILs in tumor tissue could improve DMFS (P = 0.04) and DOS (P = 0.15) in patients with high SIRI compared to those with low CD8 + TILs and high SIRI.

conclusionsIn patients with localized UPS, CD8 + TILs infiltration into the tumor tissue could improve the prognosis of patients with high SIRI.

Indexed as

CD8-Positive T-LymphocytesLymphocytes, Tumor-InfiltratingSarcomaAdolescentAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansInflammationKaplan-Meier EstimateMaleMiddle AgedNeutrophilsPrognosisBiomarkers, TumorCD8 + tumor-infiltrating lymphocyteSoft tissueSystemic inflammatory response indexUndifferentiated pleomorphic sarcoma

Identifiers

PMID41398940
PMCPMC12707010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.